Akari Therapeutics (AKTX) Upgraded by ValuEngine to Sell
ValuEngine upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a strong sell rating to a sell rating in a research note issued to investors on Thursday morning.
Several other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Akari Therapeutics from a sell rating to a hold rating and set a $5.00 target price on the stock in a research note on Monday, November 13th. Canaccord Genuity restated a buy rating and set a $15.00 price objective on shares of Akari Therapeutics in a research report on Friday, September 22nd. William Blair upgraded shares of Akari Therapeutics from a market perform rating to an outperform rating in a research report on Friday, September 22nd. Finally, Chardan Capital restated a neutral rating on shares of Akari Therapeutics in a research report on Sunday, September 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $7.50.
Akari Therapeutics (AKTX) traded down $0.02 during midday trading on Thursday, reaching $4.84. 102,461 shares of the company’s stock traded hands, compared to its average volume of 369,742. Akari Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $22.20.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Stock Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related stocks with our FREE daily email newsletter.